The core activity of Somagenetix AG is the development and research of gene therapies for genetic diseases, particularly for phagocytic disorders such as chronic granulomatous disease (CGD). The company focuses on the development of lentivirus-mediated gene therapies that are designed to offer a unique combination of safety, specificity and long-term efficacy.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Precise, one-time gene therapies for phagocyte disorders and other genetic diseases; based on lentiviral-transduced stem cells, with targeted activity in differentiated phagocytes.
PhagoCure platform
Platform for precise genetic correction in phagocytes; LV-SIN vectors, myeloid-specific and silencing-resistant promoters, designed for long-lasting effect and safety.
Development of SGX-001
Development of the lead program SGX-001 against Chronic Granulomatous Disease (CGD); preclinical, with planned entry into clinical studies.
Preclinical development of gene therapies
Preclinical in vitro and in vivo development with GLP-compliant studies, safety and efficacy testing, and validation in animal models.
Knowledge
No knowledge articles yet
Once Somagenetix AG has claimed this profile, we'll publish editorial articles and case studies here together.